News Release

Protein may hold key to decreasing organ dysfunction rates in heart transplants

Genetically disabling a protein decreases inflammation in transplanted hearts

Peer-Reviewed Publication

Blackwell Publishing Ltd.

Innsbruck, Austria – April 27, 2007 - A new study, led by Felix Aigner, M.D., has identified a protein known as Lipocalin-2 (Lcn-2) as potentially responsible for regulating the body's inflammatory response during heart transplants. One of the major complications involved with many transplantations is the damage done to the transplanted heart during and immediately following surgery, known as ischemia and reperfusion (IR). In particular, inflammatory cells infiltrate the donated heart, which then releases enzymes and other proteins that attack the transplanted tissue, and can seriously impair the viability of replacement organs and jeopardize the health of the patient. The identification of Lcn-2 could be a first step towards reducing this inflammatory response and increasing the success rate of heart transplants worldwide. The study appears in American Journal of Transplantation.

Building on earlier work, the study finds that Lcn-2 is released by inflammatory cells attacking transplanted hearts in mice, and suggests that the protein is responsible for attracting further inflammatory response. Inflammation was found to decrease dramatically in mice in which the production of Lcn-2 was genetically disabled.

The study also found elevated levels of Lcn-2 in the kidneys of mice that had undergone heart transplants, suggesting the protein's possible involvement in the systemic response to IR. "The major goal of our research activities is therefore to understand the exact mechanisms of this injury concomitant to organ transplantation," notes Aigner, stressing the value of this research to the development of new treatment options in organ transplantation.

###

The research and viewpoints expressed in the article are those of the author and do not reflect the opinions of the journal or the affiliated societies.

This study is published in the April issue of American Journal of Transplantation. Media wishing to receive a PDF of this article may contact medicalnews@bos.blackwellpublishing.net.

Felix Aigner M.D. is a researcher in the Department of General and Transplant Surgery at Innsbruck Medical University in Austria. His research into the role of Lipocalin-2 in organ transplantation has already led to collaborations with international immunology and molecular biology facilities. He can be reached for questions at felix.aigner@i-med.ac.at .


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.